ClinicalTrials.gg
TerminatedNCT05732454Updated May 8, 2025Results posted

A Study to Learn About the Study Medicine Etrasimod in Adults With Moderate to Severe Atopic Dermatitis (AD) Who Have Already Tried Treatments Taken by Mouth or by Injection

A Phase 2/3 interventional study of etrasimod and Placebo in Atopic Dermatitis, Atopic Dermatitis, Unspecified and Eczema, sponsored by Pfizer. Terminated at 74 sites in 4 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-05-08.

Sponsored by Pfizer · Phase 2/3, Interventional, and Treatment

Why this study was terminated
Per the results of the planned interim analysis, the study met futility criteria for efficacy so the trial was terminated. This decision was made for efficacy reasons only and is not due to any safety concerns.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
58
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 58 studies in Dermatitis, Atopic by Pfizer — 11 open to participants now, 13 under way, 4 of them phase 3. Dermatitis, Atopic · Pfizer.

Enrollment
33rd of 47
58 · median 121
Started
2023
with 4 others
Phase 2/3
Only one
of the 58
Registered
42nd of 58
by date

Among the 58 studies in Dermatitis, Atopic by Pfizer, this one is the 33rd largest by enrollment of the 47 interventional ones that give a count, is one of 5 that started in 2023, is the only one in phase 2/3, and was the 42nd registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

11 of the 58 studies in Dermatitis, Atopic by Pfizer are open now, in 12 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 58 studies in Dermatitis, Atopic by Pfizer, or all of them as a file.
02

Study summary

The purpose of this study is to learn about the safety and effects of the study medicine called etrasimod for the possible treatment of atopic dermatitis (AD), also called eczema, in adults who have already tried AD treatments taken by mouth or by injection that work all over the body. These adults can have moderate to severe AD.

This study is seeking participants who:

  • have AD for at least 1 year
  • have moderate-to-severe AD
  • have tried treatments that work all over the body and saw no effects
  • are willing to apply a moisturizer at least once daily during the study

This is a 2-part study that is only selecting about 60 participants for Part 1 as of now. In Part 1, half of the participants will receive etrasimod, a pill to be taken by mouth once daily. The other half will receive a placebo, a pill that looks like etrasimod but has no medicine also taken by mouth once daily. No one will know what treatment the participant is taking. The Sponsor will compare participant experiences of those taking etrasimod to those taking placebo for 16 weeks. This will help determine if the study medicine is safe and effective. After the first 16 weeks, some participants may continue the study knowing they are taking etrasimod for an additional 52 weeks.

Those participating for just the first 16-weeks, will need to visit the study clinic at least 6 times during the study (about every 4 weeks), and will have to come for 2 safety follow up visits at 2nd and 4th week after the last dose of study medicine. People who want to and can continue for an additional 52 weeks will need to visit the study clinic for at least 6 more visits making 12 total visits over 68 weeks followed by 2 safety follow up visits at the 2nd and 4th week after the last dose of study medicine.

In Part 2 of the study, around 340 more participants will be participating. Everyone will receive etrasimod pills once daily for 52 weeks. Participants will need to go to the study clinic at least 9 times after which they will have to go for 2 more safety follow up visits at the 2nd and 4th weeks after the last dose of study medicine.

At every study visit in Part 1 and Part 2, the focus will be on signs and symptoms of AD (like lesions, itch, and pain) as well as general health and overall side effects. Blood samples and vital signs will be taken at every visit. Due to the way the study medicine works, the in-study clinic visit will last at least 4 hours on Day 1 (Part 1 and Part 2) and Week 16 (Part 1).

03

Conditions studied

  • Atopic Dermatitis
  • Atopic Dermatitis, Unspecified
  • Eczema
  • Eczema, Atopic

Keywords

  • Systemic Failure
  • Oral
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants must meet the following key inclusion criteria to be eligible for enrollment into the study:

  1. Age 18-80 at screening (or minimum age of consent according to local regulations).

2 Chronic AD (also known as atopic eczema) that was diagnosed at least 1 year prior to Screening and meets Hanifin and Rajka criteria at screening).1 3. Moderate to severe AD:

  1. IGA score ≥3 (on the 0 to 4 IGA scale, in which 3 = moderate and 4 = severe) at screening and baseline (Day 1)
  2. BSA ≥10% of AD involvement at screening and baseline (Day 1)
  3. Eczema Area and Severity Index (EASI) ≥16 at screening and baseline (Day 1) 4. A participant who has failed a prior systemic therapy for AD, ie, , moderate-to-severe AD that is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable.

    1. Willing to apply a topical emollient/moisturizer at least once daily for ≥1 week prior to baseline (Day 1) and willing to maintain consistent (ie, no change in type, frequency, or application) daily application over the course of the study.

Exclusion criteria

Exclusion Criteria:

Participants are excluded from the study if any of the following criteria apply:

Medical Conditions:

  1. Presence of confounding factors:

    • Skin conditions (eg, psoriasis, seborrheic dermatitis) that may interfere with evaluation of AD or assessment of treatment response as deemed by the investigator.
    • Current significant active infection or requiring a treatment for infection that may interfere with the assessment of AD.
  2. to etrasimod or any of the .
  3. Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
58 participants (actual)

Study arms

  • Experimental
    etrasimod

    2 mg, oral tablet, once daily

    Drug: etrasimod

  • Placebo comparator
    Placebo (Part 1 DB period only)

    Oral sham comparator

    Drug: Placebo

Interventions

  • PART 1 Double Blind one 2 mg tablet once daily for up to 16 weeks PART 1 Open Label Extension one 2 mg tablet once daily for an additional 52 weeks PART 2 Open Label one 2 mg tablet once daily for up 52 weeks

    Also known as: APD334, PF-07915503

  • DrugPlacebo

    PART 1 DOUBLE BLIND Placebo - one table daily for up to 16 weeks

06

What researchers measure

Primary outcomes

  1. Part 1, DB Period: Percentage of Participants Achieving Investigator's Global Assessment (IGA) Response at Week 16

    IGA measured AD severity, based on a 5-point scale (0-4); 0= AD is clear, 1= AD is almost clear, 2= mild AD, 3= moderate AD and 4= severe AD. IGA response was defined as participants achieving IGA 0 (clear) or 1 (almost clear) and a reduction of \>=2 points from baseline.

    Time frame: DB Period: Week 16

  2. Part 1, DB Period: Number of Participants With Treatment Emergent Adverse Events (TEAEs) (All Causality)

    An adverse event (AE) was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Treatment-emergent are events between first dose of study drug and up to last dose that were absent before treatment or that worsened relative to pretreatment state.

    Time frame: DB Period: From first dose of study drug up to 16 Weeks of treatment

  3. Part 1, DB Period: Number of Participants With TEAEs (All Causality) Leading to Study Treatment Discontinuation

    An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Treatment-emergent are events between first dose of study drug and up to last dose that were absent before treatment or that worsened relative to pretreatment state.

    Time frame: DB Period: From first dose of study drug up to 16 Weeks of treatment

  4. Part 1, DB Period: Number of Participants With Treatment Emergent Serious Adverse Events (SAEs) (All Causality)

    An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Treatment-emergent are events between first dose of study drug and up to last dose that were absent before treatment or that worsened relative to pretreatment state. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; life-threatening experience (immediate risk of death); new or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect; suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic or other medical events judged by investigator.

    Time frame: DB Period: From first dose of study drug up to 16 Weeks of treatment

  5. Part 1, DB Period: Number of Participants With Treatment Emergent AEs of Special Interest (AESIs) (All Causality)

    An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Treatment-emergent are events between first dose of study drug and up to last dose that were absent before treatment or that worsened relative to pretreatment state. AESIs included here were cardiovascular events (i.e., bradycardia, Atrioventricular (AV) conduction delay, and hypertension); macular edema, pulmonary events (airflow obstruction or decreased gas exchange); infections (severe infections, opportunistic infections \[including progressive multifocal leukoencephalopathy (PML)\], Herpes simplex and Herpes zoster); liver injury (liver transaminase elevation and bilirubin elevation); posterior reversible encephalopathy syndrome (PRES) and malignancies.

    Time frame: DB Period: From first dose of study drug up to 16 Weeks of treatment

  6. Part 1, DB Period: Number of Participants With Laboratory Test Abnormalities

    Laboratory assessments included hematology, clinical chemistry, urinalysis, other parameters and reflex tests. Number of participants with abnormalities in any of laboratory parameters is reported.

    Time frame: DB Period: From first dose of study drug up to 16 Weeks of treatment

  7. Part 1, DB Period: Number of Participants With Markedly Abnormal 12-Lead Electrocardiogram Measurements and AV Blocks

    Standard 12-lead ECGs utilizing limb leads were used to measure PR interval, QT interval, QTc corrected using Fridericia's formula (QTcF), and QRS complex. Number of participants with non-zero ECG abnormalities and AV blocks are reported in this outcome measure.

    Time frame: DB Period: Pre-dose and 4 hours (hrs) post-dose on Day 1/Week 0; Pre-dose and 4 hrs post-dose on Day 113/Week 16

  8. Part 1, DB Period: Number of Participants With Markedly Abnormal Vital Sign

    Vital signs evaluation included systolic blood pressure (SBP), diastolic blood pressure (DBP), pulse rate. Number of participants with non-zero vital signs abnormalities are reported in this outcome measure.

    Time frame: DB Period: Pre-dose and 1, 2, 3, 4 hours (hrs) post-dose on Day 1/Week 0; Day 29/Week 4; Day 57/Week 8; Day 85/Week 12; Pre-dose and 1, 2, 3, 4, 5 and 6 hrs post-dose on Day 113/Week 16

  9. Part 1, OLE Period: Number of Participants With TEAEs (All Causality)

    An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Treatment-emergent are events between first dose of study drug and up to last dose that were absent before treatment or that worsened relative to pretreatment state.

    Time frame: OLE Period: First dose of study drug in OLE period up to 4 weeks after last dose in OLE period (up to maximum of 56 Weeks)

  10. Part 1, OLE Period: Number of Participants With Treatment Emergent AEs (All Causality) Leading to Study Treatment Discontinuation

    An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Treatment-emergent are events between first dose of study drug and up to last dose that were absent before treatment or that worsened relative to pretreatment state.

    Time frame: OLE Period: First dose of study drug in OLE period up to 4 weeks after last dose in OLE period (up to maximum of 56 Weeks)

  11. Part 1, OLE Period: Number of Participants With Treatment Emergent SAEs (All Causality)

    An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Treatment-emergent are events between first dose of study drug and up to last dose that were absent before treatment or that worsened relative to pretreatment state. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; life-threatening experience (immediate risk of death); new or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect; suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic or other medical events judged by investigator.

    Time frame: OLE Period: First dose of study drug in OLE period up to 4 weeks after last dose in OLE period (up to maximum of 56 Weeks)

  12. Part 1, OLE Period: Number of Participants With Treatment Emergent AESIs (All Causality)

    An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Treatment-emergent are events between first dose of study drug and up to last dose that were absent before treatment or that worsened relative to pretreatment state. AESIs included here were cardiovascular events (i.e., bradycardia, AV conduction delay, and hypertension); macular edema, pulmonary events (airflow obstruction or decreased gas exchange); infections (severe infections, opportunistic infections \[including PML\], Herpes simplex and Herpes zoster); liver injury (liver transaminase elevation and/or bilirubin elevation); PRES and malignancies.

    Time frame: OLE Period: First dose of study drug in OLE period up to 4 weeks after last dose in OLE period (up to maximum of 56 Weeks)

  13. Part 1, OLE Period: Number of Participants With Laboratory Test Abnormalities

    Laboratory assessments included hematology, clinical chemistry, urinalysis, other parameters and reflex tests. Number of participants with abnormalities in any of laboratory parameters is reported.

    Time frame: OLE Period: First dose of study drug in OLE period up to 4 weeks after last dose in OLE period (up to maximum of 56 Weeks)

  14. Part 1, OLE Period: Number of Participants With Markedly Abnormal 12-Lead Electrocardiogram Measurements and AV Blocks

    Standard 12-lead ECGs utilizing limb leads were used to measure PR interval, QT interval, QTcF, and QRS complex. Number of participants with non-zero ECG abnormalities and AV blocks are reported in this outcome measure.

    Time frame: OLE Period: Day 169/Week 24

  15. Part 1, OLE Period: Number of Participants With Markedly Abnormal Vital Sign

    Vital signs evaluation included SBP, DBP, pulse rate. Number of participants with non-zero vital signs abnormalities are reported in this outcome measure.

    Time frame: OLE Period: Day 141/Week 20; Day 169/Week 24; Day 281/Week 40; Follow Up 1; Follow Up 2

Secondary outcomes

  1. Part 1, DB Period: Percentage of Participants Who Achieved >=75% Reduction From Baseline in Eczema Area and Severity Index (EASI) Score (EASI-75) at Week 16

    EASI-75 response was defined as a 75% reduction or greater in EASI score from Baseline to Week 16. EASI quantified severity of AD based on severity of lesion clinical signs and percentage (%) of body surface area (BSA) affected. Severity of clinical signs of AD lesions (erythema \[E\], induration/papulation \[I\], excoriation \[Ex\] and lichenification \[L\]) were scored separately for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin)\] and lower limbs \[including buttocks\]) on a 4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score was based on % BSA with AD in body region: 0 (0%), 1 (\>0 to \<10%), 2 (10 to \<30%), 3 (30 to \<50%), 4 (50 to \<70%), 5 (70 to \<90%) and 6 (90 to 100%). Total EASI score =0.1\*Ah\*(Eh+Ih+Exh+Lh) + 0.2\*Au\*(Eu+Iu+ExU+Lu) + 0.3\*At\*(Et+It+Ext+Lt) + 0.4\*Al\*(El+Il+Exl+Ll); A = EASI area score; h = head and neck; u = upper limbs; t = trunk; l = lower limbs.

    Time frame: DB Period: Week 16

  2. Part 1, DB Period: Percent Change From Baseline in EASI Score at Week 16

    EASI quantified severity of AD based on severity of lesion clinical signs and percentage (%) of body surface area (BSA) affected. Severity of clinical signs of AD lesions (erythema \[E\], induration/papulation \[I\], excoriation \[Ex\] and lichenification \[L\]) were scored separately for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin)\] and lower limbs \[including buttocks\]) on a 4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score was based on % BSA with AD in body region: 0 (0%), 1 (\>0 to \<10%), 2 (10 to \<30%), 3 (30 to \<50%), 4 (50 to \<70%), 5 (70 to \<90%) and 6 (90 to 100%). Total EASI score =0.1\*Ah\*(Eh+Ih+Exh+Lh) + 0.2\*Au\*(Eu+Iu+ExU+Lu) + 0.3\*At\*(Et+It+Ext+Lt) + 0.4\*Al\*(El+Il+Exl+Ll); A = EASI area score; h = head and neck; u = upper limbs; t = trunk; l = lower limbs.

    Time frame: DB Period: Baseline, Week 16

07

Results

Posted May 8, 2025

Participant flow

The study had 2 parts: Part 1 and Part 2. Part 2 was never initiated; hence no results are reported for it. All results are pertaining to Part 1 in the record. Part 1 of the study had 16-week double-blind (DB) treatment period and then 52-week part 1 open label extension (OLE) treatment period.

Part 1: DB Period
Participant flow — Part 1: DB Period
MilestoneDB Etrasimod 2 mg Then OLE Etrasimod 2 mgDB Placebo Then OLE Etrasimod 2 mg
Started3028
Completed2725
Not completed33
Withdrew: Withdrawal by subject12
Withdrew: Adverse event10
Withdrew: Lost to follow-up10
Withdrew: Protocol violation01
Part 1: OLE Period
Participant flow — Part 1: OLE Period
MilestoneDB Etrasimod 2 mg Then OLE Etrasimod 2 mgDB Placebo Then OLE Etrasimod 2 mg
Started2724
Completed00
Not completed2724
Withdrew: Study terminated by sponsor2519
Withdrew: Withdrawal by subject23
Withdrew: Adverse event01
Withdrew: Lack of efficacy01

Outcome measures

PrimaryPart 1, DB Period: Percentage of Participants Achieving Investigator's Global Assessment (IGA) Response at Week 16

IGA measured AD severity, based on a 5-point scale (0-4); 0= AD is clear, 1= AD is almost clear, 2= mild AD, 3= moderate AD and 4= severe AD. IGA response was defined as participants achieving IGA 0 (clear) or 1 (almost clear) and a reduction of \>=2 points from baseline.

Time frame:
DB Period: Week 16
Reported as:
Number · Percentage of Participants
Part 1, DB Period: Percentage of Participants Achieving Investigator's Global Assessment (IGA) Response at Week 16
Percentage of ParticipantsDB Period: Etrasimod 2 mgDB Period: Placebo
Part 1, DB Period: Percentage of Participants Achieving Investigator's Global Assessment (IGA) Response at Week 163.3 (3.28 to —)7.1 (4.87 to —)
Statistical analysis
  • DB Period: Etrasimod 2 mg vs DB Period: Placebo · Cochran-Mantel-Haenszel · p = =0.5580 · Difference in percentage: -3.76 · 95% CI -16.36 to 8.83
SecondaryPart 1, DB Period: Percentage of Participants Who Achieved >=75% Reduction From Baseline in Eczema Area and Severity Index (EASI) Score (EASI-75) at Week 16

EASI-75 response was defined as a 75% reduction or greater in EASI score from Baseline to Week 16. EASI quantified severity of AD based on severity of lesion clinical signs and percentage (%) of body surface area (BSA) affected. Severity of clinical signs of AD lesions (erythema \[E\], induration/papulation \[I\], excoriation \[Ex\] and lichenification \[L\]) were scored separately for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin)\] and lower limbs \[including buttocks\]) on a 4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score was based on % BSA with AD in body region: 0 (0%), 1 (\>0 to \<10%), 2 (10 to \<30%), 3 (30 to \<50%), 4 (50 to \<70%), 5 (70 to \<90%) and 6 (90 to 100%). Total EASI score =0.1\*Ah\*(Eh+Ih+Exh+Lh) + 0.2\*Au\*(Eu+Iu+ExU+Lu) + 0.3\*At\*(Et+It+Ext+Lt) + 0.4\*Al\*(El+Il+Exl+Ll); A = EASI area score; h = head and neck; u = upper limbs; t = trunk; l = lower limbs.

Time frame:
DB Period: Week 16
Reported as:
Number · Percentage of Participants
Part 1, DB Period: Percentage of Participants Who Achieved >=75% Reduction From Baseline in Eczema Area and Severity Index (EASI) Score (EASI-75) at Week 16
Percentage of ParticipantsDB Period: Etrasimod 2 mgDB Period: Placebo
Part 1, DB Period: Percentage of Participants Who Achieved >=75% Reduction From Baseline in Eczema Area and Severity Index (EASI) Score (EASI-75) at Week 1623.3 (7.72 to —)14.3 (6.61 to —)
Statistical analysis
  • DB Period: Etrasimod 2 mg vs DB Period: Placebo · Cochran-Mantel-Haenszel · p = =0.3685 · Difference in percentage: 9.07 · 95% CI -10.70 to 28.85
SecondaryPart 1, DB Period: Percent Change From Baseline in EASI Score at Week 16

EASI quantified severity of AD based on severity of lesion clinical signs and percentage (%) of body surface area (BSA) affected. Severity of clinical signs of AD lesions (erythema \[E\], induration/papulation \[I\], excoriation \[Ex\] and lichenification \[L\]) were scored separately for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin)\] and lower limbs \[including buttocks\]) on a 4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score was based on % BSA with AD in body region: 0 (0%), 1 (\>0 to \<10%), 2 (10 to \<30%), 3 (30 to \<50%), 4 (50 to \<70%), 5 (70 to \<90%) and 6 (90 to 100%). Total EASI score =0.1\*Ah\*(Eh+Ih+Exh+Lh) + 0.2\*Au\*(Eu+Iu+ExU+Lu) + 0.3\*At\*(Et+It+Ext+Lt) + 0.4\*Al\*(El+Il+Exl+Ll); A = EASI area score; h = head and neck; u = upper limbs; t = trunk; l = lower limbs.

Time frame:
DB Period: Baseline, Week 16
Reported as:
Least squares mean · Percent change
Part 1, DB Period: Percent Change From Baseline in EASI Score at Week 16
Percent changeDB Period: Etrasimod 2 mgDB Period: Placebo
Part 1, DB Period: Percent Change From Baseline in EASI Score at Week 16-53.87 ± 9.007-24.65 ± 9.533
Statistical analysis
  • DB Period: Etrasimod 2 mg vs DB Period: Placebo · Rubin's rule · p = =0.0303 · Difference in mean: -29.22 · 95% CI -55.53 to -2.90
PrimaryPart 1, DB Period: Number of Participants With Treatment Emergent Adverse Events (TEAEs) (All Causality)

An adverse event (AE) was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Treatment-emergent are events between first dose of study drug and up to last dose that were absent before treatment or that worsened relative to pretreatment state.

Time frame:
DB Period: From first dose of study drug up to 16 Weeks of treatment
Reported as:
Count of participants · Participants
Part 1, DB Period: Number of Participants With Treatment Emergent Adverse Events (TEAEs) (All Causality)
ParticipantsDB Period: Etrasimod 2 mgDB Period: Placebo
Part 1, DB Period: Number of Participants With Treatment Emergent Adverse Events (TEAEs) (All Causality)168
PrimaryPart 1, DB Period: Number of Participants With TEAEs (All Causality) Leading to Study Treatment Discontinuation

An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Treatment-emergent are events between first dose of study drug and up to last dose that were absent before treatment or that worsened relative to pretreatment state.

Time frame:
DB Period: From first dose of study drug up to 16 Weeks of treatment
Reported as:
Count of participants · Participants
Part 1, DB Period: Number of Participants With TEAEs (All Causality) Leading to Study Treatment Discontinuation
ParticipantsDB Period: Etrasimod 2 mgDB Period: Placebo
Part 1, DB Period: Number of Participants With TEAEs (All Causality) Leading to Study Treatment Discontinuation10
PrimaryPart 1, DB Period: Number of Participants With Treatment Emergent Serious Adverse Events (SAEs) (All Causality)

An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Treatment-emergent are events between first dose of study drug and up to last dose that were absent before treatment or that worsened relative to pretreatment state. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; life-threatening experience (immediate risk of death); new or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect; suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic or other medical events judged by investigator.

Time frame:
DB Period: From first dose of study drug up to 16 Weeks of treatment
Reported as:
Count of participants · Participants
Part 1, DB Period: Number of Participants With Treatment Emergent Serious Adverse Events (SAEs) (All Causality)
ParticipantsDB Period: Etrasimod 2 mgDB Period: Placebo
Part 1, DB Period: Number of Participants With Treatment Emergent Serious Adverse Events (SAEs) (All Causality)00
PrimaryPart 1, DB Period: Number of Participants With Treatment Emergent AEs of Special Interest (AESIs) (All Causality)

An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Treatment-emergent are events between first dose of study drug and up to last dose that were absent before treatment or that worsened relative to pretreatment state. AESIs included here were cardiovascular events (i.e., bradycardia, Atrioventricular (AV) conduction delay, and hypertension); macular edema, pulmonary events (airflow obstruction or decreased gas exchange); infections (severe infections, opportunistic infections \[including progressive multifocal leukoencephalopathy (PML)\], Herpes simplex and Herpes zoster); liver injury (liver transaminase elevation and bilirubin elevation); posterior reversible encephalopathy syndrome (PRES) and malignancies.

Time frame:
DB Period: From first dose of study drug up to 16 Weeks of treatment
Reported as:
Count of participants · Participants
Part 1, DB Period: Number of Participants With Treatment Emergent AEs of Special Interest (AESIs) (All Causality)
ParticipantsDB Period: Etrasimod 2 mgDB Period: Placebo
Part 1, DB Period: Number of Participants With Treatment Emergent AEs of Special Interest (AESIs) (All Causality)21
PrimaryPart 1, DB Period: Number of Participants With Laboratory Test Abnormalities

Laboratory assessments included hematology, clinical chemistry, urinalysis, other parameters and reflex tests. Number of participants with abnormalities in any of laboratory parameters is reported.

Time frame:
DB Period: From first dose of study drug up to 16 Weeks of treatment
Reported as:
Count of participants · Participants
Part 1, DB Period: Number of Participants With Laboratory Test Abnormalities
ParticipantsDB Period: Etrasimod 2 mgDB Period: Placebo
Part 1, DB Period: Number of Participants With Laboratory Test Abnormalities2213
PrimaryPart 1, DB Period: Number of Participants With Markedly Abnormal 12-Lead Electrocardiogram Measurements and AV Blocks

Standard 12-lead ECGs utilizing limb leads were used to measure PR interval, QT interval, QTc corrected using Fridericia's formula (QTcF), and QRS complex. Number of participants with non-zero ECG abnormalities and AV blocks are reported in this outcome measure.

Time frame:
DB Period: Pre-dose and 4 hours (hrs) post-dose on Day 1/Week 0; Pre-dose and 4 hrs post-dose on Day 113/Week 16
Reported as:
Count of participants · Participants
Part 1, DB Period: Number of Participants With Markedly Abnormal 12-Lead Electrocardiogram Measurements and AV Blocks
ParticipantsDB Period: Etrasimod 2 mgDB Period: Placebo
Pre-dose/Day 1: AV conduction: First-degree AV Block10
4 hrs post-dose/Day 1: QTCF (msec), single beat:>= 450 (male) or >= 470 (female)10
4 hrs post-dose/Day 1: Change From Baseline (CFB) in QT: >30 msec increase90
4 hrs post-dose/Day 1: AV conduction: First degree AV Block30
Pre-dose/Week 16: CFB in QT: >30 msec increase10
Pre-dose/Week 16: CFB in QT: >60 msec increase10
Pre-dose/Week 16: CFB in QTcF: >30 msec increase20
4 hrs post-dose/Week 16: CFB in QTcF: >30 msec increase20
4 hrs post-dose/Week 16: CFB in QT: >30 msec increase20
4 hrs post-dose/Week 16: AV conduction: First degree AV Block20
PrimaryPart 1, DB Period: Number of Participants With Markedly Abnormal Vital Sign

Vital signs evaluation included systolic blood pressure (SBP), diastolic blood pressure (DBP), pulse rate. Number of participants with non-zero vital signs abnormalities are reported in this outcome measure.

Time frame:
DB Period: Pre-dose and 1, 2, 3, 4 hours (hrs) post-dose on Day 1/Week 0; Day 29/Week 4; Day 57/Week 8; Day 85/Week 12; Pre-dose and 1, 2, 3, 4, 5 and 6 hrs post-dose on Day 113/Week 16
Reported as:
Count of participants · Participants
Part 1, DB Period: Number of Participants With Markedly Abnormal Vital Sign
ParticipantsDB Period: Etrasimod 2 mgDB Period: Placebo
Pre-dose/Day 1: DBP >90 mmHg01
Pre-dose/Day 1: Pulse rate: <60 bpm13
Pre-dose/Day 1: Pulse rate >100 bpm10
1 hr post-dose/Day 1: SBP: Change >=30 mmHg decrease01
1 hr post-dose/Day 1: DBP >90 mmHg22
1 hr post-dose/Day 1: Pulse rate: <50 bpm10
1 hr post-dose/Day 1: Pulse rate: <60 bpm73
2 hrs post-dose/Day 1: SBP: >150 mmHg02
2 hrs post-dose/Day 1: DBP >90 mmHg01
2 hrs post-dose/Day 1: Pulse rate: <60 bpm125
3 hrs post-dose/Day 1:SBP >150 mmHg01
3 hrs post-dose/Day 1: SBP: Change>=30 mmHg decrease10
3 hrs post-dose/Day 1: DBP:>90 mmHg01
3 hrs post-dose/Day 1: DBP: Change>=20 mmHg decrease20
3 hrs post-dose/Day 1: Pulse rate: <60 bpm116
4 hrs post-dose/Day 1: DBP: >90 mmHg11
4 hrs post-dose/Day 1: Pulse rate: <60 bpm105
4 hrs post-dose/Day 1: Pulse rate: >100 bpm10
Week 4: DBP:>90 mmHg23
Week 4: Pulse rate: <60 bpm21
Week 4: Pulse rate: >100 bpm10
Week 8: SBP: >150 mmHg01
Week 8: DBP:>90 mmHg33
Week 8: DBP: Change >=20 mmHg decrease01
Week 8: Pulse rate: <60 bpm31
Week 12: SBP: >150 mmHg01
Week 12: DBP:>90 mmHg13
Week 12: Pulse rate: <60 bpm10
Week 12: Pulse rate: >100 bpm02
Pre-dose/Week 16: SBP: >150 mmHg01
Pre-dose/Week 16: DBP: >90 mmHg20
Pre-dose/Week 16: Pulse rate: <60 bpm22
1 hr post dose/Week 16: SBP: >150 mmHg01
1 hr post-dose/Week 16: SBP: Change >=30 mmHg decrease01
1 hr post dose/Week 16: DBP: >90 mmHg21
1 hr post dose/Week 16: Pulse rate: <50 bpm11
1 hr post dose/Week 16: Pulse rate: <60 bpm34
2 hrs post dose/Week 16: SBP: >150 mmHg01
2 hrs post-dose/Week 16: SBP: Change >=30 mmHg decrease02
2 hrs post dose/Week 16: DBP: >90 mmHg22
2 hrs post dose/Week 16: Pulse rate: <50 bpm01
2 hrs post dose/Week 16: Pulse rate: <60 bpm310
3 hrs post dose/Week 16:DBP: >90 mmHg20
3 hrs post dose/Week 16: Pulse rate: <50 bpm01
3 hrs post dose/Week 16: Pulse rate: <60 bpm39
4 hrs post dose/Week 16: SBP: >150 mmHg01
4 hrs post dose/Week 16: DBP:>90 mmHg20
4 hrs post-dose/Week 16: DBP: Change >=20 mmHg decrease01
4 hrs post dose/Week 16: Pulse rate: <50 bpm01
4 hrs post dose/Week 16: Pulse rate:<60 bpm16
5 hrs post dose/Week 16:Pulse rate:<50 bpm01
5 hrs post dose/Week 16:Pulse rate:<60 bpm01
6 hrs post dose/Week 16:Pulse rate:<50 bpm01
6 hrs post dose/Week 16: Pulse rate:<60 bpm01
PrimaryPart 1, OLE Period: Number of Participants With TEAEs (All Causality)

An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Treatment-emergent are events between first dose of study drug and up to last dose that were absent before treatment or that worsened relative to pretreatment state.

Time frame:
OLE Period: First dose of study drug in OLE period up to 4 weeks after last dose in OLE period (up to maximum of 56 Weeks)
Reported as:
Count of participants · Participants
Part 1, OLE Period: Number of Participants With TEAEs (All Causality)
ParticipantsOLE Period: Etrasimod 2 mg (Etrasimod 2 mg in DB Period)OLE Period: Etrasimod 2 mg (Placebo in DB Period)
Part 1, OLE Period: Number of Participants With TEAEs (All Causality)95
PrimaryPart 1, OLE Period: Number of Participants With Treatment Emergent AEs (All Causality) Leading to Study Treatment Discontinuation

An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Treatment-emergent are events between first dose of study drug and up to last dose that were absent before treatment or that worsened relative to pretreatment state.

Time frame:
OLE Period: First dose of study drug in OLE period up to 4 weeks after last dose in OLE period (up to maximum of 56 Weeks)
Reported as:
Count of participants · Participants
Part 1, OLE Period: Number of Participants With Treatment Emergent AEs (All Causality) Leading to Study Treatment Discontinuation
ParticipantsOLE Period: Etrasimod 2 mg (Etrasimod 2 mg in DB Period)OLE Period: Etrasimod 2 mg (Placebo in DB Period)
Part 1, OLE Period: Number of Participants With Treatment Emergent AEs (All Causality) Leading to Study Treatment Discontinuation01
PrimaryPart 1, OLE Period: Number of Participants With Treatment Emergent SAEs (All Causality)

An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Treatment-emergent are events between first dose of study drug and up to last dose that were absent before treatment or that worsened relative to pretreatment state. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; life-threatening experience (immediate risk of death); new or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect; suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic or other medical events judged by investigator.

Time frame:
OLE Period: First dose of study drug in OLE period up to 4 weeks after last dose in OLE period (up to maximum of 56 Weeks)
Reported as:
Count of participants · Participants
Part 1, OLE Period: Number of Participants With Treatment Emergent SAEs (All Causality)
ParticipantsOLE Period: Etrasimod 2 mg (Etrasimod 2 mg in DB Period)OLE Period: Etrasimod 2 mg (Placebo in DB Period)
Part 1, OLE Period: Number of Participants With Treatment Emergent SAEs (All Causality)10
PrimaryPart 1, OLE Period: Number of Participants With Treatment Emergent AESIs (All Causality)

An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Treatment-emergent are events between first dose of study drug and up to last dose that were absent before treatment or that worsened relative to pretreatment state. AESIs included here were cardiovascular events (i.e., bradycardia, AV conduction delay, and hypertension); macular edema, pulmonary events (airflow obstruction or decreased gas exchange); infections (severe infections, opportunistic infections \[including PML\], Herpes simplex and Herpes zoster); liver injury (liver transaminase elevation and/or bilirubin elevation); PRES and malignancies.

Time frame:
OLE Period: First dose of study drug in OLE period up to 4 weeks after last dose in OLE period (up to maximum of 56 Weeks)
Reported as:
Count of participants · Participants
Part 1, OLE Period: Number of Participants With Treatment Emergent AESIs (All Causality)
ParticipantsOLE Period: Etrasimod 2 mg (Etrasimod 2 mg in DB Period)OLE Period: Etrasimod 2 mg (Placebo in DB Period)
Part 1, OLE Period: Number of Participants With Treatment Emergent AESIs (All Causality)10
PrimaryPart 1, OLE Period: Number of Participants With Laboratory Test Abnormalities

Laboratory assessments included hematology, clinical chemistry, urinalysis, other parameters and reflex tests. Number of participants with abnormalities in any of laboratory parameters is reported.

Time frame:
OLE Period: First dose of study drug in OLE period up to 4 weeks after last dose in OLE period (up to maximum of 56 Weeks)
Reported as:
Count of participants · Participants
Part 1, OLE Period: Number of Participants With Laboratory Test Abnormalities
ParticipantsOLE Period: Etrasimod 2 mg (Etrasimod 2 mg in DB Period)OLE Period: Etrasimod 2 mg (Placebo in DB Period)
Part 1, OLE Period: Number of Participants With Laboratory Test Abnormalities2018
PrimaryPart 1, OLE Period: Number of Participants With Markedly Abnormal 12-Lead Electrocardiogram Measurements and AV Blocks

Standard 12-lead ECGs utilizing limb leads were used to measure PR interval, QT interval, QTcF, and QRS complex. Number of participants with non-zero ECG abnormalities and AV blocks are reported in this outcome measure.

Time frame:
OLE Period: Day 169/Week 24
Reported as:
Count of participants · Participants
Part 1, OLE Period: Number of Participants With Markedly Abnormal 12-Lead Electrocardiogram Measurements and AV Blocks
ParticipantsOLE Period: Etrasimod 2 mg (Etrasimod 2 mg in DB Period)OLE Period: Etrasimod 2 mg (Placebo in DB Period)
Week 24: QTCF (msec), single beat:>= 450 (male) or >= 470 (female)10
Week 24: CFB in QTcF: >30 sec increase10
Week 24: CFB in QT: >30 msec increase20
Week 24: CFB in QT: >60 msec increase10
PrimaryPart 1, OLE Period: Number of Participants With Markedly Abnormal Vital Sign

Vital signs evaluation included SBP, DBP, pulse rate. Number of participants with non-zero vital signs abnormalities are reported in this outcome measure.

Time frame:
OLE Period: Day 141/Week 20; Day 169/Week 24; Day 281/Week 40; Follow Up 1; Follow Up 2
Reported as:
Count of participants · Participants
Part 1, OLE Period: Number of Participants With Markedly Abnormal Vital Sign
ParticipantsOLE Period: Etrasimod 2 mg (Etrasimod 2 mg in DB Period)OLE Period: Etrasimod 2 mg (Placebo in DB Period)
Week 20: SBP: >150 mmHg11
Week 20: SBP: Change:>=30 mmHg decrease01
Week 20: DBP: >90 mmHg21
Week 20: Pulse rate: <60 bpm10
Week 24: SBP: >150 mmHg01
Week 24: SBP: Change:>=30 mmHg decrease01
Week 24: DBP: >90 mmHg11
Week 24: DBP: Change>=20 mmHg decrease01
Week 24: Pulse rate: <60 bpm11
Week 32: DBP: >90 mmHg10
Week 40: DBP: >90 mmHg10
Follow-up 1: DBP: >90 mmHg20
Follow-up 1: Pulse rate: <60 bpm12
Follow-up 2: DBP: >90 mmHg20
Follow-up 2: Pulse rate: <60 bpm12

Adverse events

Collected over Part 1, DB Period: Day 1 to Week 16; Part 1, OLE Period: Week 20 to Week 68; Part 1, DB +OLE Period: Day 1 to Week 68. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
DB Period: Etrasimod 2 mg0/30 (0%)0/30 (0%)6/30 (20%)
DB Period: Placebo0/28 (0%)0/28 (0%)4/28 (14.3%)
OLE Period: Etrasimod 2 mg (Etrasimod 2 mg in DB Period)0/30 (0%)1/30 (3.3%)4/30 (13.3%)
OLE Period: Etrasimod 2 mg (Placebo in DB Period)0/28 (0%)0/28 (0%)1/28 (3.6%)
DB Etrasimod 2 mg Then OLE Etrasimod 2 mg0/30 (0%)1/30 (3.3%)9/30 (30%)
DB Placebo Then OLE Etrasimod 2 mg0/28 (0%)0/28 (0%)5/28 (17.9%)
Most frequent serious events
Most frequent serious events
EventDB Period: Etrasimod 2 mgDB Period: PlaceboOLE Period: Etrasimod 2 mg (Etrasimod 2 mg in DB Period)OLE Period: Etrasimod 2 mg (Placebo in DB Period)DB Etrasimod 2 mg Then OLE Etrasimod 2 mgDB Placebo Then OLE Etrasimod 2 mg
Pneumothorax spontaneousRespiratory, thoracic and mediastinal disorders0/300/281/300/281/300/28
Most frequent other events
Most frequent other events
EventDB Period: Etrasimod 2 mgDB Period: PlaceboOLE Period: Etrasimod 2 mg (Etrasimod 2 mg in DB Period)OLE Period: Etrasimod 2 mg (Placebo in DB Period)DB Etrasimod 2 mg Then OLE Etrasimod 2 mgDB Placebo Then OLE Etrasimod 2 mg
HypertensionVascular disorders1/302/282/300/283/302/28
Dermatitis atopicSkin and subcutaneous tissue disorders2/301/280/301/282/302/28
COVID-19Infections and infestations2/300/280/300/282/300/28
NasopharyngitisInfections and infestations2/301/280/300/282/301/28
Respiratory tract infectionInfections and infestations0/300/282/300/282/300/28

Baseline characteristics

The full analysis set (FAS) included all participants who were randomized to the study irrespective of whether they received any dose of study intervention (i.e., Etrasimod or placebo). Participants were analyzed in the treatment groups as they were randomized.

Age, Continuous
Age, Continuous(Years)DB Etrasimod 2 mg Then OLE Etrasimod 2 mgDB Placebo Then OLE Etrasimod 2 mgTotal
Mean40.0 ± 14.7843.4 ± 18.1841.6 ± 16.45
Sex: Female, Male
Sex: Female, Male(Participants)DB Etrasimod 2 mg Then OLE Etrasimod 2 mgDB Placebo Then OLE Etrasimod 2 mgTotal
Female21930
Male91928
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)DB Etrasimod 2 mg Then OLE Etrasimod 2 mgDB Placebo Then OLE Etrasimod 2 mgTotal
Hispanic or Latino5510
Not Hispanic or Latino252348
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)DB Etrasimod 2 mg Then OLE Etrasimod 2 mgDB Placebo Then OLE Etrasimod 2 mgTotal
American Indian or Alaska Native000
Asian303
Native Hawaiian or Other Pacific Islander000
Black or African American314
White242751
More than one race000
Unknown or Not Reported000
08

Study locations

74 sites
  • First OC Dermatology Research Inc
    Fountain Valley, California 92708, United States
  • Jared R. Younger, MD (Ophthalmologist)
    Fountain Valley, California 92708, United States
  • Bryan D. Vo. MD (Pulmonologist)
    Laguna Hills, California 92653, United States
  • California Allergy and Asthma Medical Group
    Los Angeles, California 90025, United States
  • Dr. Carolyn M. Wong
    Los Angeles, California 90025, United States
  • Dr. Gerald Markovitz
    Los Angeles, California 90025, United States
  • Resolution Advanced Imaging Center
    Santa Monica, California 90404, United States
  • Ponce PFT & Medical services, INC [for pulmonology examination]
    Aventura, Florida 33180, United States
  • Advanced Eye Center: Rodrigo Belalcazar, MD
    Hialeah, Florida 33012, United States
  • Direct Helpers Research Center
    Hialeah, Florida 33012, United States
  • Gsi Clinical Research
    Margate, Florida 33063, United States
  • Randy Burks, MD, FACS
    Margate, Florida 33063, United States
  • D & H National Research Centers, Inc.
    Miami, Florida 33155, United States
  • Imaging - Advanced Health Imaging
    Miami, Florida 33155, United States
  • The Selem Center [Ophthalmologist JOSEPH SELEM]
    Miami, Florida 33165, United States
  • Miami Dermatology and Laser Research
    Miami, Florida 33173, United States
  • Ophthalmology - Dr. Edward Boshnick's Global Vision Rehabilitation Center
    Miami, Florida 33173, United States
  • Pulmonology - Miami Pulmonology Specialists
    Miami, Florida 33173, United States
  • Pelletier Jesse MD
    North Miami Beach, Florida 33162, United States
  • Santos Carlos R MD
    North Miami Beach, Florida 33162, United States
  • Tory Sullivan, Md Pa
    North Miami Beach, Florida 33162, United States
  • Gateway Radiology
    Pinellas Park, Florida 33781, United States
  • Hull & Hull Medical Specialists
    Plantation, Florida 33324, United States
  • GCP Research, Global Clinical professionals
    Saint Petersburg, Florida 33705, United States
  • St. Anthonys Hospital
    Saint Petersburg, Florida 33705, United States
  • USF Health
    Tampa, Florida 33612, United States
  • Lung and Sleep Disorder Center
    Lathrup Village, Michigan 48076, United States
  • Revival Research Institute, LLC
    Troy, Michigan 48084, United States
  • Somerset Opthalmology PC
    Troy, Michigan 48084, United States
  • Eye Institute
    Tulsa, Oklahoma 74136, United States
  • Pulmonary and Sleep Center of Oklahoma
    Tulsa, Oklahoma 74136, United States
  • Vital Prospects Clinical Research Institute, PC
    Tulsa, Oklahoma 74136, United States
  • Monument Health Rapid City Hospital
    Rapid City, South Dakota 57701, United States
  • Health Concepts
    Rapid City, South Dakota 57702, United States
  • In Vision Optical and Eyecare
    Rapid City, South Dakota 57702, United States
  • Eye Care Associates of Arlington
    Arlington, Texas 76010, United States
  • Arlington Research Center
    Arlington, Texas 76011, United States
  • Texas Pulmonary
    Arlington, Texas 76012, United States
  • Alpesh D. Desai, DO PLLC
    Houston, Texas 77008, United States
  • Becky Fredrickson, MD [Optometrist/Ophthalmologist]
    Houston, Texas 77008, United States
  • Rupesh Vakil, MD [Pulmonologist]
    Houston, Texas 77008, United States
  • Acclaim Dermatology
    Sugar Land, Texas 77479, United States
  • Horizon Eye Care and Optical
    Sugar Land, Texas 77479, United States
  • Sweetwater Pulmonary Associates
    Sugar Land, Texas 77479, United States
  • Rejuvenation Dermatology
    Edmonton, Alberta T5J 3S9, Canada
  • CaRe Clinic
    Red Deer, Alberta T4P 1K4, Canada
  • Visique
    Québec, Quebec G2J 0C4, Canada
  • Biron
    Quebec, G1W 2K9, Canada
  • Alpha Recherche Clinique
    Quebec, G2J 0C4, Canada
  • Poliklinika VEKTOR Pardubice
    Pardubice, 53002, Czechia
  • Pratia Pardubice a.s.
    Pardubice, 53002, Czechia
  • Fakultní nemocnice v Motole
    Praha 5, 150 06, Czechia
  • Cityclinic Przychodnia Lekarsko-Psychologiczna Matusiak Spółka Partnerska
    Wroclaw, Dolnośląskie 50-566, Poland
  • Artemed Centrum Medyczne
    Wrocław, Dolnośląskie 50-450, Poland
  • Specjalistyczna Praktyka Lekarska Joanna Kalinowska
    Wrocław, Dolnośląskie 51-605, Poland
  • Indywidualna Specjalistyczna Praktyka Lekarska Michał Silber
    Wrocław, Dolnośląskie 53-124, Poland
  • DERMEDIC Iwona Zdybska
    Lublin, Lubelskie 20-607, Poland
  • Eyemed
    Lublin, Lubelskie 20-631, Poland
  • Centrum Medyczne ,,All - Med'' Badania Kliniczne
    Kraków, Małopolskie 30-033, Poland
  • Centrum Medyczne Dietla 19
    Kraków, Małopolskie 31-070, Poland
  • AUGON Gabinet Okulistyczny
    Bialystok, Podlaskie 15-427, Poland
  • Nzoz Specjalistyczny Ośrodek Dermatologiczny "Dermal"
    Bialystok, Podlaskie 15-453, Poland
  • Gabinet Alergologiczny IR-med dr n. med. Izabela Roszko-Kirpsza
    Bialystok, Podlaskie 15-872, Poland
  • Flosmed
    Poznan, Wielkopolskie 60-192, Poland
  • Niepubliczny Zakład Opieki Zdrowotnej Zespół Poradni Specjalistycznych "Termedica"
    Poznan, Wielkopolskie 60-681, Poland
  • Medoculis
    Poznań, Wielkopolskie 61-551, Poland
  • Medicus
    Szczecin, Zachodniopomorskie 70-233, Poland
  • Twoja Przychodnia SCM
    Szczecin, Zachodniopomorskie 71-500, Poland
  • Gabinety Lekarskie Rivermed
    Poznan, 61-441, Poland
  • Centrum Medyczne Szpital Świętej Rodziny
    Łódź, Łódzkie 90-302, Poland
  • Dermoklinika - Centrum Medyczne spółka cywilna M. Kierstan, J. Narbutt, A. Lesiak
    Łódź, Łódzkie 90-436, Poland
  • Ekovivus
    Łódź, Łódzkie 91-833, Poland
  • Centrum Medyczne Angelius Provita
    Katowice, Śląskie 40-611, Poland
  • Centrum Zdrowia Ochaliczówka
    Katowice, Śląskie 40-750, Poland
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2023 to primary completion in Apr 2024, 15 months.

Results were first posted in May 2025, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 22, 2022
First posted
Feb 17, 2023
StartActual
Jan 18, 2023
Primary completionActual
Apr 29, 2024
CompletionActual
Apr 29, 2024
Results first posted
May 8, 2025
Last update
May 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05732454
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Feb 17, 2023
Start date
Jan 18, 2023
Primary completion
Apr 29, 2024
Completion
Apr 29, 2024
Results posted
May 8, 2025
Last update
May 8, 2025

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Etrasimod

Start the discussion